Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved βto help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.β
SPONSORED CONTENTHow can you help new pet owners keep their new dogs protected?See why new dog owners and their pets can benefit from simple triple protection in one monthly chew. + See the Difference